Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics reports developments as a clinical-stage biopharmaceutical company focused on neuropsychiatric diseases. Its recurring news centers on CYC-126, a lead program for treatment-resistant depression, including FDA interactions, clinical development planning, advisory-board activity, and work on an anesthesia-enabled therapeutic approach.
Company updates also cover licensing and collaboration agreements, including technology rights for neuropsychiatric disorders and closed-loop anesthetic delivery, as well as the ongoing management of legacy soluble guanylate cyclase, or sGC, assets such as praliciguat and olinciguat. Governance changes, board composition, shareholder matters, expense management, and capital-structure disclosures are recurring themes in Cyclerion’s public-company communications.
Cyclerion Therapeutics (Nasdaq: CYCN) has appointed Dr. Steven E. Hyman to its Board of Directors, effective July 25, 2022. Dr. Hyman, a notable figure in neuroscience, will assist in shaping the company’s research and clinical strategies while enhancing external collaborations. His expertise in developing treatments for neuropsychiatric diseases will be vital as Cyclerion advances its lead molecule, CY6463, targeting cognitive dysfunction. Cyclerion focuses on therapies for conditions such as Alzheimer's and Mitochondrial Encephalomyopathy.
Cyclerion Therapeutics (CYCN) announced positive results from a signal-seeking Phase 2a study of CY6463, a CNS-penetrant sGC stimulator for MELAS patients. Conducted with eight participants, the study showed CY6463 was well-tolerated, with no serious adverse events reported. Improvements were noted across various mitochondrial disease biomarkers and cerebral blood flow metrics after 29 days of treatment. The findings support further investigation of CY6463 as a potential therapy for MELAS, addressing the significant unmet need for effective treatment options.
Cyclerion Therapeutics (NASDAQ: CYCN) will present positive topline data from its Phase 2a study of CY6463 in MELAS patients during a webinar on June 28, 2022. The study aims to evaluate the safety and effectiveness of CY6463, a CNS-penetrant sGC stimulator. Amel Karaa, M.D., will discuss the implications of the findings for MELAS patients, who currently have no approved therapies. The study involved eight adults and could signal a new therapeutic option for this debilitating condition.
Cyclerion Therapeutics (Nasdaq: CYCN) reported promising preclinical results for its sGC stimulator, CY6463, showing improved cellular energetics and reduced inflammation in mitochondrial disease models. Notably, CY6463 increased ATP levels and restored mitochondrial gene expression in patients with mitochondrial complex 1 deficiency. These findings support ongoing clinical studies for treating CNS diseases associated with mitochondrial dysfunction. The data was presented at the 10th International Conference on cGMP in Germany on June 17, 2022.
Cyclerion Therapeutics announced positive topline data from a Phase 2a study of CY6463, an oral treatment for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the open-label study involving eight patients, CY6463 showed improvements in biomarkers related to mitochondrial function, inflammation, and cerebral blood flow after 29 days of treatment. The drug was well tolerated with no serious adverse events. These results support further development of CY6463 as a potential treatment option for MELAS and other CNS diseases associated with mitochondrial dysfunction.
Cyclerion Therapeutics (Nasdaq: CYCN) announced significant updates ahead of the UMDF Mitochondrial Medicine 2022 Symposium from June 8-11, 2022. Chad Glasser, Director of Clinical Research, will present topline data from the MELAS clinical study on June 10, 2022. Additionally, Dr. Leonard Burg will showcase preclinical data demonstrating that CY6463 improves function in zebrafish disease models on June 9, 2022. CY6463 is being developed as a first-in-class treatment for various CNS diseases, specifically targeting cognitive function restoration.
Cyclerion Therapeutics (Nasdaq: CYCN) recently announced progress in clinical development for its lead program, CY6463, focused on cognitive function restoration. Enrollment closed for two studies: MELAS, with topline data expected in Q2 2022, and CIAS, with results anticipated in Q3 2022. The Alzheimer's Disease with vascular pathology (ADv) trial is still recruiting. Financially, CYCN reported a Q1 2022 net loss of approximately $13 million, slightly lower than Q1 2021. Cash reserves stood at about $41 million, down from $54 million at the end of 2021.
Cyclerion Therapeutics has provided updates on its clinical development pipeline for CY6463, focusing on cognitive impairment linked to CNS diseases. Enrollment for the Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) Phase 2a study has closed, with topline data expected in Q2 2022. The Cognitive Impairment Associated with Schizophrenia (CIAS) study is ongoing, with topline data anticipated in H2 2022. The Alzheimer’s Disease with vascular pathology (ADv) study is also active. Financially, Cyclerion reported a net loss of $51.6 million for 2021, a decrease from $77.8 million in 2020.
Cyclerion Therapeutics and Ariana Pharma announced a collaboration to leverage artificial intelligence for identifying patient-selection biomarkers. This partnership aims to enhance the clinical development of Cyclerion's investigational drug, CY6463, targeting neurological and neuropsychiatric diseases related to cognitive impairment. The AI technology used will analyze data from previous clinical studies to accelerate CY6463's development and optimize patient targeting, ultimately aiming for effective treatments.
Cyclerion Therapeutics has commenced patient dosing in its Phase 2a study for Alzheimer’s Disease with Vascular Pathology (ADv), assessing CY6463. This randomized, placebo-controlled trial aims to evaluate the tolerability, safety, and pharmacokinetics of CY6463 over 12 weeks. The study targets around 30 participants with confirmed Alzheimer’s pathology and cardiovascular risk factors. Preliminary studies indicate the potential of CY6463 to improve cognitive function by leveraging the NO-sGC-cGMP signaling pathway.